POS0652 LONG-TERM EFFECTIVENESS OF ULTRA-LOW DOSES OF RITUXIMAB IN RHEUMATOID ARTHRITIS
Authors: N. Den Broeder, L. M. Verhoef, Y. A. De Man, M. R. Kok, R. M. Thurlings, W. Van der Weele, B. Van den Bemt, F. Van den Hoogen, A. Van der Maas, A. Den Broeder
Journal: Annals of the Rheumatic Diseases (2022)

Background The optimal rituximab (RTX) dose for the treatment of rheumatoid arthritis remains unclear. RTX treatment of 1000mg per 6 months and 2000mg per 6 months were shown to be similarly efficacious (1). The REDO trial showed comparable the 6-month efficacy of continued treatment with 500mg and 200mg compared to 1000mg, though formal non-inferiority could not be established (2). Objectives To assess the long-term effects of ultra-low dose RTX (1×500mg and 1×200mg) in RA patients previously responding well to conventional low dose RTX (1×1000mg). Methods Patients from the REDO trial were invited to participate in this study. Treatment decisions were left at the discretion of the rheumatologist and patient. Disease activity (DAS28-CRP), and medication use (b/tsDMARD, csDMARD, gluccocorticoids [GC]) were collected from start of the trial to censoring in April 2021. The primary outcome was disease activity, secondary outcomes were RTX persistence, RTX doses and intervals, and use of comedication. Disease activity was analyzed using a longitudinal mixed model with random intercepts to account for intra-patient correlations, in two ways: 1. By original randomization and stratification factors (RF/ACPA and csDMARD use). 2. By time-varying total RTX dose received in the year preceding each disease activity measurement, adjusted for current csDMARD or GC use, and RF/ACPA. The original DAS28-CRP non-inferiority (NI) margin of 0.6 was used. Results 118 out of 142 REDO patients were included in current analyses (Table 1) Reasons for exclusion were: continuing treatment elsewhere (n=3), no informed consent (n=9) and data yet to be collected in 2 study centers (n=12). Mean follow up was 3.2 years (total of 377 patient-years), with 7 patients switching to another b/tsDMARD (Figure 1) upon which they were censored from disease activity analyses. Table 1. Patient characteristics by original randomization 1000mg (n=24) 500mg (n=48) 200mg (n=46) Age (years) 65 (9) 64 (11) 64 (12) Female 15 (63%) 28 (58%) 34 (74%) Meeting ACR1987 or ACRU/EULAR 2010 RA criteria 22 (92%) 47 (98%) 43 (93%) Disease duration (years) 14 (9-24) 14 (7-21) 13 (8-20) RF or ACPA positive 22 (92%) 44 (92%) 40 (87%) Duration of rituximab use (years) 3.0 (1.6-5.5) 2.0 (1.0-5.5) 3.7 (2.0-5.7) Concomitant csDMARD 17 (71%) 29 (60%) 27 (59%) Previous number of b/tsDMARDs used 2 (2-2) 2 (1-3) 2 (1-2) Previous number of csDMARDs used 3 (1-3) 2 (1-4) 3 (1-3) Oral GC use at baseline 3 (13%) 8 (17%) 5 (11%) Baseline DAS28-CRP 2.3 (0.9) 2.3 (0.9) 2.5 (1.1) Data are n (%), mean (SD), or median (IQR). Figure 1. Rituximab treatment persistence during follow up. Disease activity in both ultra-low dose groups was non-inferior to the 1000mg group, with a mean DAS28-CRP (95% CI) during follow-up of 2.2 (2.0-2.4) in the 1000mg group, 2.2 (2.1-2.4) in the 500mg group and 2.3 (2.2-2.5) in the 200mg group. Analyzed by received RTX dose, lower RTX dose was significantly associated with a higher DAS28-CRP: 0.15 (95% CI: 0.04-0.26) points higher per 1000mg more RTX. The upper limit for relevant RTX doses was below the prespecified NI margin, excluding a relevant effect of RTX dose on disease activity. Median (IQR) yearly RTX dose was 978mg (704mg-1425mg). Final RTX dose per infusion was 200mg in 37 patients (31%), 500mg in 47 (40%) and 1000mg in 34 (29%), with a median (IQR) final interval between infusions of 6.0 (5.7-6.5), 6.2 (6.0-7.4) and 6.4 (6.0-9.6) months respectively. The rate of GC injections was 0.38 (95% CI: 0.32-0.44) per patient-year and initiation rate of oral GC was 0.05 (0.03-0.08) per patient-year. Conclusion A majority of patients treated with ultra-low dose RTX remained on ultra-low doses for up to 4 years, while disease activity remained low and did not relevantly differ between RTX doses, either according to original randomization or by received dose. Switching to other b/tsDMARDS or use of GC was rarely required. References [1]Bredemeier M et al. Clin Rheumatol 2015 Oct;34(10):1801-5. [2]Verhoef LM et al. Lancet Rheumatol. 2019; 1: e145-e153. Disclosure of Interests Nathan den Broeder: None declared, L.M. Verhoef: None declared, Yaël A. de Man: None declared, Marc R Kok: None declared, R.M. Thurlings: None declared, W. van der Weele: None declared, Bart van den Bemt Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen and Eli Lilly, Frank van den Hoogen: None declared, Aatke van der Maas: None declared, Alfons den Broeder Grant/research support from: Abbvie, Galapagos, Pfizer, Novartis, Lilly, Sanofi, Gilead